News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zealand Pharma Informs of New Sanofi (France) (SAN.PA) Scientific Presentations for Lyxumia® and of Own Presentation of a Novel Zealand Liquid Glucagon Analogue at the American Diabetes Association’s 73rd Scientific Sessions


6/17/2013 9:07:52 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs of a series of data relating to Lyxumia® (lixisenatide), a GLP-1 receptor agonist discovered by Zealand and licensed globally to Sanofi, and of new data on a preclinical Zealand pipeline program to be presented at the American Diabetes Association’s (ADA) 73rd Scientific Sessions taking place on 21-25 June 2013 in Chicago, US. The titles of the presentations follow.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES